Shareholders of Sarepta Therapeutics (Nsadaq: SRPT) could be excused for scratching their heads yesterday after the close when the common stock of the company traded down around 10% after what seemed to be positive news emanating from the FDA. In a highly anticipated press release, Sarepta announced the results of the company’s meeting with the FDA regarding the pathway to eventual approval for eteplirsen, a novel exon-skipping drug that shows tremendous promise in treating boys suffering from Duchenne’s Muscular Dystrophy (“DMD”).
The options market proves the old adage that there is no such thing as a free lunch. Investors who dabble in special situations expect that the marketplace knows the basic outlines of your thesis, and prices risk accordingly. That’s not to say you can’t make money betting on outcomes, just that the firms on the other side taking your wager always make sure that the table pays odds commiserate with the gamble.
(November 23, 2012) Last night’s Patriot rout of the sad-sack New York Jets had all the hallmarks of a turkey. As someone who shelled out green to see some green action I had seen enough red on the field for one night so I strolled on over to the Verizon Studio to check out the latest handsets on display. As expected, people were milling about playing with the dozens of new phones and tables on display, preferring the indoor digital toys to the schoolyard romp taking place outside.